Testing for epidermal growth factor receptor (EGFR) mutations is an essential recommendation in guidelines for metastatic non-squamous non-small-cell lung cancer, and is considered mandatory in European countries. The gene discussed is EGFR; the disease is non-small cell squamous lung carcinoma.